Remove Resources Preclinical
article thumbnail

HanAll Biopharma and Daewoong sign deal to develop Parkinson’s therapy

Pharmaceutical Technology

HanAll Biopharma and Daewoong Pharmaceutical will combine their resources and knowledge to develop NurrOn’s ATH-399A and other compounds targeting Nurr1 [nuclear receptor-related 1 protein] to treat neurodegenerative disorders. They will help to progress ATH-399A towards a Phase I trial.

article thumbnail

InvisiShield and Gladstone partner to develop intranasal preventatives

Pharmaceutical Technology

Scientists at Gladstone Institutes will be responsible for carrying out preclinical studies to assess the efficacy and safety of the product. Under the partnership terms, InvisiShield will offer technical support, as well as funding to develop the intranasal preventatives.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds July 15, 2022: Overview of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Public-Private Partnership and Lessons Learned (Stacey J. Adam, PhD)

Rethinking Clinical Trials

There were four ACTIV fast-track focus areas: vaccines, preclinical, clinical trial capacity, and therapeutics – clinical. Candidate agents were triaged based on concurrent clinical trials, completion of a multiple ascending dose study, and availability of preclinical data before being scored based on predefined criteria.

article thumbnail

Intrinsic Medicine enters merger with Phoenix Biotech

Pharmaceutical Technology

The merged business’ cash resources are estimated to offer Intrinsic the capital to progress its lead compound, OM002, and other pipeline assets. These resources will also be used to fund a Phase IIb clinical trial of OM002 in more than 400 subjects with constipation dominant form of irritable bowel syndrome (IBS-C).

Medicine 147
article thumbnail

Reaction Biology to acquire Vyant Bio subsidiary’s operations in US

Pharmaceutical Technology

This investment in talent, infrastructure and resources is an important step in our roadmap for fully realising Reaction’s potential as a provider of solutions for the discovery and development of new drug candidates.”.

In-Vivo 130
article thumbnail

AI development duo to advance drug-metabolising enzymes 

Drug Discovery World

The study demonstrates novel predictive models for AO, FMO, and UGT metabolism, and extends the existing model for CYP metabolism to preclinical species. In silico modelling for CYP in preclinical species can also reduce animal testing in toxicology studies, making trials quicker, less expensive, and more ethical. .

article thumbnail

Strategies for Successful Navigation of Complex Radiopharmaceutical Trials

Worldwide Clinical Trials

For example, initiating early engagement with regulatory bodies during the preclinical phase can clarify expectations and shape study design, setting your trial up for smoother development with fewer back and forth exchanges. One such approach is standardizing imaging protocols across your trial sites — consistency is key.

Trials 183